GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of §§10 (b) and 20 ...

GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Check the time stamp on this data. Updated AI-Generated Signals for Gsk Plc American Depositary Shares (each Representing Two) (GSK) available here: GSK. Type a few symbols and Take a Trial. The ...

GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.

If you suffered losses exceeding $75,000 in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plc (NYSE:GSK – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $34.84, but opened at $37.06.

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...